Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Alvotech

33,40 SEK

-3,19 %

Mindre end 1K følgere

ALVO SDB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Sammenligne
-3,19 %
-23,05 %
-28,08 %
-36,38 %
-55,37 %
-
-
-
-66,02 %

Alvotech is a biotechnology company that focuses on the development and manufacture of biosimilar medicines. The company's pipeline consists of biosimilar candidates aimed at treating autoimmune diseases, eye diseases, osteoporosis and cancer. The company offers its products to patients all over the world. Alvotech was founded in 2013 and has its headquarters in Reykjavík.

Læs mere
Markedsværdi
10,85 mia. SEK
Aktieomsætning
275,04 t SEK
Omsætning
5,43 mia.
EBIT %
14,33 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mia.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
19.3
2026

Årsrapport '25

7.5
2026

Delårsrapport Q1'26

20.8
2026

Delårsrapport Q2'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse4.3.2026, 08.00

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Alvotech
Selskabsmeddelelse26.2.2026, 21.00

Transactions of Managers and Closely Associated Persons

Alvotech
Selskabsmeddelelse11.2.2026, 16.00

Alvotech Announces Increase in Number of Own Shares

Alvotech

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse5.2.2026, 08.00

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Alvotech
Selskabsmeddelelse2.2.2026, 08.00

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Alvotech
Selskabsmeddelelse29.1.2026, 08.00

Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg

Alvotech
Selskabsmeddelelse7.1.2026, 22.00

Correction: Transactions of Managers and Closely Associated Persons

Alvotech
Selskabsmeddelelse6.1.2026, 20.00

Transactions of Managers and Closely Associated Persons

Alvotech
Selskabsmeddelelse6.1.2026, 20.00

Transactions of Managers and Closely Associated Persons

Alvotech
Selskabsmeddelelse6.1.2026, 12.15

Alvotech announces planned CEO succession and leadership transition

Alvotech
Selskabsmeddelelse31.12.2025, 21.30

Alvotech Secures Term Loan Facility of USD 100 Million

Alvotech
Selskabsmeddelelse29.12.2025, 19.40

Changes in company's own shares

Alvotech
Selskabsmeddelelse22.12.2025, 20.26

Alvotech’s Financial Calendar for 2026

Alvotech
Selskabsmeddelelse22.12.2025, 07.00

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Alvotech
Selskabsmeddelelse19.12.2025, 08.30

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Alvotech
Selskabsmeddelelse17.12.2025, 07.30

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Alvotech
Selskabsmeddelelse16.12.2025, 16.48

Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance

Alvotech
Selskabsmeddelelse24.11.2025, 10.30

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Alvotech
Selskabsmeddelelse20.11.2025, 09.00

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Alvotech
Selskabsmeddelelse12.11.2025, 21.40

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Alvotech
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.